Literature DB >> 10825048

Failure of physicians to consider the diagnosis of pertussis in children.

S Deeks1, G De Serres, N Boulianne, B Duval, L Rochette, P Déry, S Halperin.   

Abstract

To determine the ability of physicians to make a diagnosis of pertussis and factors associated with improved diagnosis, 8,235 children from 88 child care centers and 14 elementary schools from Quebec City, Quebec, Canada, were evaluated by using a questionnaire completed by parents and a medical record review. Children must have consulted a physician to be included in the evaluation. There were 558 children meeting the surveillance case definition and 416 meeting a modified World Health Organization case definition who consulted a physician. A diagnosis of pertussis was considered in 24%-26% of children meeting either case definition, made in 12%-14%, and reported for 6%. Pertussis diagnosis was significantly associated with having a history of pertussis exposure (P < or = .003), four pertussis-related symptoms (P < .001), and a cough for > or = 5 weeks (P < or = .05) and consulting in a hospital setting (P < or = .03). The proportion of cases of pertussis diagnosed and reported is low even when children present with classical symptoms.

Entities:  

Mesh:

Year:  1999        PMID: 10825048     DOI: 10.1086/515203

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

1.  Economic evaluation of a new acellular vaccine for pertussis in Canada.

Authors:  M Iskedjian; T R Einarson; B J O'Brien; J G De Serres; R Gold; I M Gemmill; N Milkovich; A Rosner
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  External quality assessment for molecular detection of Bordetella pertussis in European laboratories.

Authors:  G Muyldermans; O Soetens; M Antoine; S Bruisten; B Vincart; F Doucet-Populaire; N K Fry; P Olcén; J M Scheftel; J M Senterre; A van der Zee; M Riffelmann; D Piérard; S Lauwers
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

3.  Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.

Authors:  Michael Iskedjian; John H Walker; Gaston De Serres; Thomas R Einarson
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Pertussis mortality and public misperceptions.

Authors:  Rolando Ulloa-Gutierrez
Journal:  CMAJ       Date:  2008-08-26       Impact factor: 8.262

5.  Pertussis serodiagnosis in Belgium from 1990 to 2009.

Authors:  Muriel Vincent; Caroline Rodeghiero; Romain Eylenbosch; Yvan Mans; Jeannine Swalus-Steenhouwer; Denis Piérard; Kris Huygen; Raymond Vanhoof
Journal:  Clin Vaccine Immunol       Date:  2011-02-23

6.  Multitarget PCR for diagnosis of pertussis and its clinical implications.

Authors:  Xuan Qin; Emmanouil Galanakis; Emily T Martin; Janet A Englund
Journal:  J Clin Microbiol       Date:  2006-12-06       Impact factor: 5.948

7.  Issues associated with and recommendations for using PCR to detect outbreaks of pertussis.

Authors:  Fabio A Lievano; Meredith A Reynolds; Alfred L Waring; Joel Ackelsberg; Kristine M Bisgard; Gary N Sanden; Dalya Guris; Anne Golaz; Dianna J Bopp; Ronald J Limberger; Perry F Smith
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

Review 8.  Pertussis: Microbiology, Disease, Treatment, and Prevention.

Authors:  Paul E Kilgore; Abdulbaset M Salim; Marcus J Zervos; Heinz-Josef Schmitt
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

9.  Prolonged Pertussis Outbreak in Ontario Originating in an Under-immunized Religious Community.

Authors:  S L Deeks; G H Lim; R Walton; J Fediurek; F Lam; C Walker; J Walters; N S Crowcroft
Journal:  Can Commun Dis Rep       Date:  2014-02-07

10.  Epidemiology of pertussis in adolescents and adults in Turkey.

Authors:  A Karagul; D Ogunc; K Midilli; G Ongut; B Ozhak Baysan; L Donmez; D Daglar; M A Kuskucu; A Bingol; O Ozbudak; D Colak; F Gunseren
Journal:  Epidemiol Infect       Date:  2014-12-19       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.